Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27237436 | 1.00 | GCGR (0.50) | GCGRHDAC6KMT2AMEN1MGAM | |
| SCHEMBL27237428 | 0.91 | KMT2A (0.58) | HDAC6KMT2AMEN1MGAMPOLB | |
| SCHEMBL25002984 | 0.91 | KMT2A (0.58) | HDAC6KMT2AMEN1MGAMPOLB | |
| SCHEMBL27237491 | 0.87 | GCGR (0.50) | GCGRKMT2AMEN1MGAMPOLB | |
| SCHEMBL31213276 | 0.87 | GCGR (0.50) | GCGRKMT2AMEN1MGAMPOLB | |
| SCHEMBL25003163 | 0.87 | GCGR (0.50) | GCGRKMT2AMEN1MGAMPOLB | |
| SCHEMBL25003168 | 0.87 | HDAC6 (0.51) | HDAC6KMT2AMEN1MGAMPOLB | |
| SCHEMBL27237402 | 0.87 | HDAC6 (0.51) | HDAC6KMT2AMEN1MGAMPOLB | |
| SCHEMBL25003164 | 0.86 | HDAC6 (0.53) | HDAC6KMT2AMEN1MGAMPOLB | |
| SCHEMBL27237430 | 0.86 | HDAC6 (0.53) | HDAC6KMT2AMEN1MGAMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335420-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-10-10 | — | — | US | claimed |
| EP-4382101-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2024-06-12 | — | — | EP | claimed |
| CN-118076347-A | N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same | 欧罗法玛实验室股份公司 | 2024-05-24 | — | — | CN | claimed |
| US-20240335420-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-10-10 | — | — | US | disclosed |
| EP-4382101-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118076347-A | N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same | 欧罗法玛实验室股份公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023010192-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335420-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS | SCN1A, SCN1B, CACNA1B | GCGR 2242/4885HDAC6 308/4885KMT2A 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.